APPENDIX I

IN THE CLAIMS

Please enter the amendments to the claims below:

60. (Amended) A method for inhibiting $\alpha_v\beta_5$ mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_5$ antagonist.

61. (Amended) The method [for inhibiting angiogenesis] of claim 60 wherein said antagonist is a matrix metalloproteinase polypeptide that includes an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 19, 20, 21 or 22[, wherein said antagonist is a fusion protein containing said matrix metalloproteinase polypeptide, a polypeptide, a derivatized polypeptide, a cyclic polypeptide, a monoclonal antibody or an organic mimetic compound].

62. (Amended) The method [for inhibiting angiogenesis] of claim 60 wherein said integrin $\alpha_v\beta_5$ antagonist preferentially inhibits fibrinogen binding to $\alpha_v\beta_5$ compared to fibrinogen binding to $\alpha_{IIb}\beta_3$.

64. (Twice Amended) The method of claim [61] 87 wherein said organic mimetic comprises the organic compounds selected from the group consisting of compounds 7, 9, 10, 12, and 14[, 15, 16, 17 and 18].

Appendix II

COPY OF PAPERS
ORIGINALLY FILED

The claims as currently pending (4/19/02)

60. A method for inhibiting $\alpha_v\beta_5$ mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_5$ antagonist.

61. (Amended) The method of claim 60 wherein said antagonist is a matrix metalloproteinase polypeptide that includes an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 15, 17, 19, 20, 21 or 22.

62. (Amended) The method for inhibiting angiogenesis of claim 60 wherein said integrin $\alpha_v\beta_5$ antagonist preferentially inhibits fibrinogen binding to $\alpha_v\beta_5$ compared to fibrinogen binding to $\alpha_{IIb}\beta_3$.

64. (Twice Amended) The method of claim 87 wherein said organic mimetic comprises the organic compounds selected from the group consisting of compounds 7, 9, 10, 12, and 14.

65. The method of claim 60 wherein said tissue is human tissue.

66. The method of claim 65 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

67. The method of claim 60 wherein said tissue is arthritic.

68. The method of claim 67 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

69. The method of claim 60 wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

70. The method of claim 69 wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

71. The method of claim 60 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

72. The method of claim 71 wherein said tissue is a carcinoma.

73. The method of claim 71 wherein said solid tumor is a tumor of lung,

pancreas, breast, colon, larynx or ovary.

74. The method of claim 71 wherein said administering is conducted in conjunction with chemotherapy.

75. The method of claim 60 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

76. The method of claim 60 wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

77. The method of claim 60 wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

78. The method of claim 60 wherein said administering comprises a single dose intravenously.

79. The method of claim 60 wherein said administering comprises one or more dose administrations daily for one or more days.

80. The method of claim 60 wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

81. The method of claim 60 wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.

82. The method of claim 60 wherein said angiogenesis is induced by a cytokine.

83. The method of claim 82 wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor.

84. The method of claim 82 wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue

angiogenesis.

85. (new) The method for inhibiting angiogenesis of claim 60 wherein said antagonist is a polypeptide or a cyclic polypeptide.

86. (new) The method for inhibiting angiogenesis of claim 60 wherein said antagonist is a monoclonal antibody.

87. (new) The method for inhibiting angiogenesis of claim 60 wherein said antagonist is a organic mimetic compound.